Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05244980 · ClinicalTrials.gov registry record · Phase 1
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 1 study of Alopecia, Androgenetic, sponsored by Technoderma Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT05244980: Completed Phase 1 study of Alopecia, Androgenetic, sponsored by Technoderma Medicines.
NCT05244980 is a Phase 1 study of Alopecia, Androgenetic that has completed, run by Technoderma Medicines. The registered enrollment target is 32 participants, below the 339-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05244980, a Phase 1 study of Alopecia, Androgenetic, has completed, sponsored by Technoderma Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
Primary Outcome
Collection of adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TDM-105795
Study Locations (2)
California
- TCR Medical Corporation - San Diego
Texas
- J&S Studies, Inc. - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
What the finished NCT05244980 record still lists
NCT05244980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 339-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Alopecia, Androgenetic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05244980 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT05244980 about?
NCT05244980 is a clinical study titled "A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)". Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
What is the current status of trial NCT05244980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-02-01. Estimated completion is 2023-02-27.
What conditions does trial NCT05244980 study?
This clinical trial studies the following conditions: Alopecia, Androgenetic.
What interventions are being tested in trial NCT05244980?
The interventions under investigation include: Placebo (DRUG), TDM-105795 (DRUG).
Who is sponsoring clinical trial NCT05244980?
This trial is sponsored by Technoderma Medicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05244980 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia, Androgenetic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
COMPLETED · Phase 2
-
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI